Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

Now watching

Next video starts in : 7 Play

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs
Replay video
Up next

United Technologies, Data: What to Watch on Wall Street April 21

Unlock your personal NFL Now stream by signing in to NFL.com

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

by TheStreet 0:49 mins

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

by TheStreet 0:49 mins

Bristol-Myers Squibb's murky earnings report reveals a company still in flux. Earnings were slightly above analyst estimates at 48 cents a share. The company's revenue came in at $3.9 billion, down 4% from the same quarter last year. The sales decline is a result of the company selling its stake in a diabetes alliance with AstraZeneca. The company's CEO said, "During the second quarter we delivered strong financial and operating results, invested in key business development opportunities, and achieved important regulatory milestones..." Bristol-Myers is hopeful of winning regulatory approval for its new immunotherapy treatment in the next year as the company looks to narrow its focus on cancer drugs. TheStreet’s Julie Cerullo reports from New York.

TheStreet

Market Movers

  1. 14:01

    Wall Street's China Boost; Hasbro gains from boys' toys; Target's Lilly Pulitzer sales craze

  2. 1:48

    Morgan Stanley's 'strongest quarter in years'; Hasbro's boy power; Raytheon gets into cybersecurity

  3. 2:35

    Target's Lilly Pulitzer line overwhelmed by demand

  4. 2:17

    Comcast and Time Warner Cable to meet with Justice Department: Report

  5. 1:57

    Raytheon planning new cyber security venture

  6. 1:46

    Jon Corzine seeks to launch hedge fund: Report